Form 4: Dyne Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 11, 2024, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,081 shares of common stock at a weighted average price of $25.7 per share.
- The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on December 10, 2021, and December 9, 2022.
- The sale was conducted automatically under a pre-existing arrangement consistent with Rule 10b5-1(c).
- Following the transaction, Beskrovnaya beneficially owns 152,352 shares, including 136,165 unvested RSUs.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations). It doesn't indicate positive or negative sentiment towards the company's prospects.
Industry Context
This is a routine transaction for executives to cover tax obligations related to stock-based compensation. It doesn't necessarily reflect a change in the executive's confidence in the company.
Stakeholder Impact
- The sale of shares by an executive could have a minor, temporary impact on the stock price.
Key Dates
| Date | Description |
|---|---|
| December 10, 2021 | Date of restricted stock unit grant. |
| December 9, 2022 | Date of restricted stock unit grant. |
| March 11, 2024 | Date of share sale transaction. |
| March 12, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.